CA
NZ
UK
AU
IND
US
● The offering raised about $175 million at $21.00 per share.
● The company launched its melanoma therapy commercially in the US.
● No confirmed company-specific catalyst was identified behind the advance.
● Reaching an event count triggers a pre-specified data analysis.
Rapport Therapeutics, Inc. (NASDAQ:RAPP) shares were trading at USD 22.91 on October 28, 2026, down 16.83%, with a relative volume at time of 4.32. The clinical-stage biotechnology company licensed RAP-219 rights in parts of Asia in March 2026, initiated its Phase 3 program in …
Replimune Group, Inc. (NASDAQ:REPL) shares were trading at USD 15.40 on October 28, 2026, up 18.01%, with a relative volume at time of 4.35. The oncolytic immunotherapy company announced FDA accelerated approval of TUDRIQEV on August 6, completed a stock offering on August 10 …
Schrodinger, Inc. (NASDAQ:SDGR) shares were trading at USD 30.16 on October 28, 2026, up 12.87%, with a relative volume at time of 3.07. The computational drug discovery company filed its Form 10-Q for the quarter ended June 30, 2026 on August 5, which reported …
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) shares were trading at USD 10.15 on October 28, 2026, down 16.56%, with a relative volume at time of 4.18. The clinical-stage oncology company's latest periodic report is its quarterly report for the period ended June 30, 2026, …
Solventum (NYSE:SOLV) shares were trading at USD 82.14 on October 28, 2026, down 1.02%, alongside one-year basic EPS growth of 275.10%, a trailing twelve-month P/E of 10.42 and a PEG ratio of 0.00 on an expected basis, the three figures behind its place among …
One-year earnings growth of 64.50%, paired with a trailing twelve-month P/E of 10.43 and an expected-basis PEG of 0.00, puts Tenet Healthcare (NYSE:THC) among undervalued growth stocks, with shares trading at USD 268.96 on October 28, 2026, up 2.64%. In its latest disclosures, the …
Please wait processing your request...